All news

Jasper wraps 18-patient kidney study, valued at

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

Jasper Therapeutics completed enrollment of 18 patients in a Phase 2 kidney study, with its stock valued at USD 17.7 million. The company expects interim data by year-end 2026 and plans further clinical development. Despite a recent "Outperform" rating, the company faces financing risks related to a large private placement and an authorized reverse stock split.

Read original source

JSPR company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.